newsOnivyde® (irinotecan liposome injection) treatment regimen significantly improved survival in…
23 January 2023 | By Catherine Eckford (European Pharmaceutical Review)
Onivyde® (irinotecan liposome injection) treatment regimen significantly improved survival in a Phase III trial compared to nab-paclitaxel plus gemcitabine.